155 related articles for article (PubMed ID: 17914091)
1. Bicalutamide increases phospho-Akt levels through Her2 in patients with prostate cancer.
Festuccia C; Gravina GL; Muzi P; Pomante R; Ventura L; Vessella RL; Vicentini C; Bologna M
Endocr Relat Cancer; 2007 Sep; 14(3):601-11. PubMed ID: 17914091
[TBL] [Abstract][Full Text] [Related]
2. Carbidopa enhances antitumoral activity of bicalutamide on the androgen receptor-axis in castration-resistant prostate tumors.
Thomas C; Wafa LA; Lamoureux F; Cheng H; Fazli L; Gleave ME; Rennie PS
Prostate; 2012 Jun; 72(8):875-85. PubMed ID: 22072572
[TBL] [Abstract][Full Text] [Related]
3. Surgical and biologic outcomes after neoadjuvant bicalutamide treatment in prostate cancer.
Gravina GL; Festuccia C; Galatioto GP; Muzi P; Angelucci A; Ronchi P; Costa AM; Bologna M; Vicentini C
Urology; 2007 Oct; 70(4):728-33. PubMed ID: 17991545
[TBL] [Abstract][Full Text] [Related]
4. Pathological effects of prostate cancer correlate with neuroendocrine differentiation and PTEN expression after bicalutamide monotherapy.
Ham WS; Cho NH; Kim WT; Ju HJ; Lee JS; Choi YD
J Urol; 2009 Oct; 182(4):1378-84. PubMed ID: 19683286
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo effects of bicalutamide on the expression of TrkA and P75 neurotrophin receptors in prostate carcinoma.
Festuccia C; Gravina GL; Muzi P; Pomante R; Ventura L; Ricevuto E; Vicentini C; Bologna M
Prostate; 2007 Sep; 67(12):1255-64. PubMed ID: 17596848
[TBL] [Abstract][Full Text] [Related]
6. Bicalutamide demonstrates biologic effectiveness in prostate cancer cell lines and tumor primary cultures irrespective of Her2/neu expression levels.
Gravina GL; Festuccia C; Millimaggi D; Tombolini V; Dolo V; Vicentini C; Bologna M
Urology; 2009 Aug; 74(2):452-7. PubMed ID: 19285710
[TBL] [Abstract][Full Text] [Related]
7. Spotlight on bicalutamide 150mg in the treatment of locally advanced prostate cancer.
Wellington K; Keam SJ
Drugs Aging; 2007; 24(2):169-71. PubMed ID: 17313204
[TBL] [Abstract][Full Text] [Related]
8. Gefitinib and bicalutamide show synergistic effects in primary cultures of prostate cancer derived from androgen-dependent naive patients.
Festuccia C; Gravina GL; Muzi P; Biordi L; Ronchi P; Martella O; Vicentini C; Bologna M
Oncol Rep; 2007 Nov; 18(5):1321-7. PubMed ID: 17914592
[TBL] [Abstract][Full Text] [Related]
9. Antagonistic interaction between bicalutamide (Casodex) and radiation in androgen-positive prostate cancer LNCaP cells.
Quéro L; Giocanti N; Hennequin C; Favaudon V
Prostate; 2010 Mar; 70(4):401-11. PubMed ID: 19902473
[TBL] [Abstract][Full Text] [Related]
10. PXD101 potentiates hormonal therapy and prevents the onset of castration-resistant phenotype modulating androgen receptor, HSP90, and CRM1 in preclinical models of prostate cancer.
Gravina GL; Marampon F; Muzi P; Mancini A; Piccolella M; Negri-Cesi P; Motta M; Lenzi A; Di Cesare E; Tombolini V; Jannini EA; Festuccia C
Endocr Relat Cancer; 2013 Jun; 20(3):321-37. PubMed ID: 23507703
[TBL] [Abstract][Full Text] [Related]
11. Salvage therapy with bicalutamide 150 mg in nonmetastatic castration-resistant prostate cancer.
Lodde M; Lacombe L; Fradet Y
Urology; 2010 Nov; 76(5):1189-93. PubMed ID: 20303155
[TBL] [Abstract][Full Text] [Related]
12. 5-Azacitidine restores and amplifies the bicalutamide response on preclinical models of androgen receptor expressing or deficient prostate tumors.
Gravina GL; Marampon F; Di Staso M; Bonfili P; Vitturini A; Jannini EA; Pestell RG; Tombolini V; Festuccia C
Prostate; 2010 Aug; 70(11):1166-78. PubMed ID: 20333699
[TBL] [Abstract][Full Text] [Related]
13. Antitumor effects of carnertinib in castration resistant prostate cancer models: a comparative study with erlotinib.
Gravina GL; Marampon F; Piccolella M; Biordi L; Ficorella C; Motta M; Jannini EA; Tombolini V; Festuccia C
Prostate; 2011 Oct; 71(14):1481-91. PubMed ID: 21446006
[TBL] [Abstract][Full Text] [Related]
14. Androgen deprivation and androgen receptor competition by bicalutamide induce autophagy of hormone-resistant prostate cancer cells and confer resistance to apoptosis.
Boutin B; Tajeddine N; Vandersmissen P; Zanou N; Van Schoor M; Mondin L; Courtoy PJ; Tombal B; Gailly P
Prostate; 2013 Jul; 73(10):1090-102. PubMed ID: 23532738
[TBL] [Abstract][Full Text] [Related]
15. Studies with CWR22 xenografts in nude mice suggest that ZD1839 may have a role in the treatment of both androgen-dependent and androgen-independent human prostate cancer.
Sirotnak FM; She Y; Lee F; Chen J; Scher HI
Clin Cancer Res; 2002 Dec; 8(12):3870-6. PubMed ID: 12473602
[TBL] [Abstract][Full Text] [Related]
16. Antiandrogen bicalutamide promotes tumor growth in a novel androgen-dependent prostate cancer xenograft model derived from a bicalutamide-treated patient.
Yoshida T; Kinoshita H; Segawa T; Nakamura E; Inoue T; Shimizu Y; Kamoto T; Ogawa O
Cancer Res; 2005 Nov; 65(21):9611-6. PubMed ID: 16266977
[TBL] [Abstract][Full Text] [Related]
17. Effect of nonsteroidal antiandrogen monotherapy versus castration therapy on neuroendocrine differentiation in prostate carcinoma.
Sciarra A; Di Silverio F
Urology; 2004 Mar; 63(3):523-7. PubMed ID: 15028450
[TBL] [Abstract][Full Text] [Related]
18. Microtubule-associated protein tau (MAPT) promotes bicalutamide resistance and is associated with survival in prostate cancer.
Sekino Y; Han X; Babasaki T; Goto K; Inoue S; Hayashi T; Teishima J; Shiota M; Takeshima Y; Yasui W; Matsubara A
Urol Oncol; 2020 Oct; 38(10):795.e1-795.e8. PubMed ID: 32430253
[TBL] [Abstract][Full Text] [Related]
19. Micellar delivery of bicalutamide and embelin for treating prostate cancer.
Danquah M; Li F; Duke CB; Miller DD; Mahato RI
Pharm Res; 2009 Sep; 26(9):2081-92. PubMed ID: 19415464
[TBL] [Abstract][Full Text] [Related]
20. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system.
Culig Z; Hoffmann J; Erdel M; Eder IE; Hobisch A; Hittmair A; Bartsch G; Utermann G; Schneider MR; Parczyk K; Klocker H
Br J Cancer; 1999 Sep; 81(2):242-51. PubMed ID: 10496349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]